Literature DB >> 6340331

Monoclonal antibodies to baculovirus structural proteins: determination of specificities by Western blot analysis.

A W Hohmann, P Faulkner.   

Abstract

Conventional mouse hybridoma technology was utilized to produce a panel of monoclonal antibodies which reacted with baculovirus proteins. Using an enzyme-linked immunosorbent assay (ELISA), the hybridomas which were raised against polyhedrin from Autographa californica nuclear polyhedrosis virus (AcNPV) and Choristoeura fumiferana nuclear polyhedrosis virus (CfNPV) were found to cross-react differentially with polyhedrins and granulins from several species of baculoviruses. Hybridoma antibodies which reacted against the nonoccluded form (NOV) of AcNPV in an ELISA test expressed different specificities for the occluded form of the virus (OV), a mutant strain of AcNPV, and CfNPV. Four hybridoma clones produced antibody which neutralized the infectivity of AcNPV NOV. One hybridoma antibody reacted strongly with the uninfected Spodoptera frugiperda host cell line. Using Western blot analysis, it was shown that hybridoma antibodies against polyhedrin reacted differentially with the complete polypeptide and protease-generated fragments of polyhedrin. The polypeptide specificity of 19 of 28 hybridoma antibodies which reacted with OV and NOV of AcNPV was assigned using Western blot analysis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340331     DOI: 10.1016/0042-6822(83)90214-3

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  64 in total

1.  Stable cell lines expressing baculovirus P35: resistance to apoptosis and nutrient stress, and increased glycoprotein secretion.

Authors:  G Lin; G Li; R R Granados; G W Blissard
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-05       Impact factor: 2.416

2.  Improved glycosylation of a foreign protein by Tn-5B1-4 cells engineered to express mammalian glycosyltransferases.

Authors:  K Breitbach; D L Jarvis
Journal:  Biotechnol Bioeng       Date:  2001-08-05       Impact factor: 4.530

3.  Ac23, an envelope fusion protein homolog in the baculovirus Autographa californica multicapsid nucleopolyhedrovirus, is a viral pathogenicity factor.

Authors:  Oliver Y Lung; Marilyn Cruz-Alvarez; Gary W Blissard
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Cellular VPS4 is required for efficient entry and egress of budded virions of Autographa californica multiple nucleopolyhedrovirus.

Authors:  Zhaofei Li; Gary W Blissard
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

5.  Palmitoylation of the Autographa californica multicapsid nucleopolyhedrovirus envelope glycoprotein GP64: mapping, functional studies, and lipid rafts.

Authors:  Sandy Xiaoxin Zhang; Yu Han; Gary W Blissard
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Baculovirus gp64 envelope glycoprotein is sufficient to mediate pH-dependent membrane fusion.

Authors:  G W Blissard; J R Wenz
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Functional analysis of the putative fusion domain of the baculovirus envelope fusion protein F.

Authors:  Marcel Westenberg; Frank Veenman; Els C Roode; Rob W Goldbach; Just M Vlak; Douwe Zuidema
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Replication patterns and cytopathology of cells infected with baculoviruses.

Authors:  G V Williams; P Faulkner
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

9.  Suppression of apoptosis in insect cells stably transfected with baculovirus p35: dominant interference by N-terminal sequences p35(1-76).

Authors:  J L Cartier; P A Hershberger; P D Friesen
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  The apoptotic suppressor P35 is required early during baculovirus replication and is targeted to the cytosol of infected cells.

Authors:  P A Hershberger; D J LaCount; P D Friesen
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.